Bedrijfsoverzicht
Entera Bio Ltd. is a clinical stage biotechnology enterprise focused on the development of oral peptides and protein replacement therapies for the healthcare market, both within Israel and on an international basis. The company's primary asset under development is EB613, an oral teriparatide formulation that has successfully completed Phase II clinical trials for the treatment of osteoporosis and a Phase I clinical trial for other indications. This biotechnology firm operates within the broader healthcare sector, specifically navigating the high-risk, high-reward environment of the biotechnology industry where significant research and development capital is required to advance therapeutic candidates from laboratory stages to regulatory approval. As of the latest reported data, the company maintains a market capitalization of $62.62M, generates annual revenue of $42,000, and employs a workforce of 20 individuals. These valuation and revenue figures indicate that Entera Bio Ltd. is a small-cap entity with limited current commercial scale, suggesting that its market position is currently defined by its potential future value derived from its pipeline rather than established cash-generating operations.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $42,000 while posting a net income of $-11,439,000, a disparity that reveals a cost structure dominated by substantial research and development expenses that far exceed current sales generation. Correspondingly, the EBITDA stands at $-11,499,000, and the free cash flow is recorded at $-11,443,625, indicating that the company consumes cash at a rate nearly equivalent to its total operating losses, which severely limits its current financial flexibility without external capital injections. The gross margin is listed at 0.0%, reflecting the typical cost of goods sold dynamics in early-stage biotechnology where production costs may not yet be optimized or scaled against revenue, while the operating margin is a negative 27450.0% and the profit margin is 0.0%, highlighting the extreme operational inefficiency relative to current sales volume due to high fixed costs. On the balance sheet, the company holds $7.11M in cash against $490,000 in debt, resulting in a debt-to-equity ratio of 3.74, which suggests a highly leveraged position relative to its equity base despite the low absolute debt amount. The current ratio stands at 6.94, indicating that the company possesses ample short-term assets to cover its short-term liabilities, providing a buffer for liquidity needs despite the cash burn. Return on equity is -108.0% and return on assets is -56.8%, metrics that reveal that management effectiveness is currently measured by the ability to sustain operations and advance clinical trials rather than by generating returns on invested capital, as both metrics are deeply negative due to the lack of profitability.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to the absence of net income, while the forward P/E is -2.09, implying that the market is pricing the company based on future expectations of earnings that are not yet realized, a common characteristic for clinical stage firms that have not yet achieved profitability. The price-to-book ratio is 4.05, indicating that the market values the company at a significant premium over its book value, likely reflecting the high potential value assigned to its intellectual property and clinical pipeline assets rather than its tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 1490.89 and an EV/EBITDA of -4.09 suggest that traditional valuation methods are less applicable, as investors are paying a multiple of sales that is extremely high relative to current revenue, driven entirely by the speculative nature of the drug development pipeline. The stock's 52-week high is $3.22 and the 52-week low is $0.91, meaning the current price sits at a level that fluctuates significantly within this range, reflecting the volatility typical of small-cap biotechnology stocks without consistent earnings. The beta value is 1.54, which indicates that the stock's price volatility is 54% higher than the broader market, suggesting that the company's share price is highly sensitive to market shifts and specific biotechnology sector news.
Growth & Income
The revenue growth year-over-year is -100.0% and the earnings growth year-over-year is N/A, indicating that the company has likely not generated significant revenue in the current reporting period compared to the previous year, a common pattern for companies transitioning between clinical phases where revenue recognition is sporadic or minimal. Since earnings growth is N/A, it is not possible to determine if earnings are growing faster or slower than revenue in a traditional sense, as the lack of earnings reflects the company's pre-revenue or near-pre-revenue status typical of clinical stage biotechnology firms. The dividend yield is N/A and the payout ratio is 0.0%, which confirms that the company does not distribute dividends to shareholders, as it retains all available cash to fund its operations and research and development activities. Consequently, the company reinvests its earnings, or rather its remaining cash reserves, entirely into growth initiatives such as advancing clinical trials for EB613 rather than paying dividends, prioritizing long-term asset development over immediate income distribution to investors.